中国血液净化

中国血液净化 ›› 2022, Vol. 21 ›› Issue (05): 305-308.doi: 10.3969/j.issn.1671-4091.2022.05.001

• 专题与讲座 •    下一篇

慢性肾脏病高磷血症的研究进展

陈亚菲,左力   

  1. 北京大学人民医院
  • 收稿日期:2021-12-23 修回日期:2022-03-06 出版日期:2022-05-12 发布日期:2022-05-12
  • 通讯作者: 左力 E-mail:ZuoLiMD@Hotmail.com
  • 基金资助:
    肝素类物质对导致骨质疏松的机制研究

Research updates on hyperphosphatemia in Chronic kidney disease

CHENYa-fei1,ZUOL   

  1. Depart mentofNephrology,PekingUniversityPeople’sHospital
  • Received:2021-12-23 Revised:2022-03-06 Online:2022-05-12 Published:2022-05-12
  • Supported by:
    国家自然科学基金面上项目(81870524)

PDF

523

摘要： 慢性肾脏病(chronickidneydisease,CKD)患病率高，随肾功能下降，磷代谢异常逐渐加重。我国CKD伴高磷血症呈患病率高、达标率低的特点。高磷血症是慢性肾脏病患者肾病进展、继发性甲状旁腺功能亢进(secondaryhyperparathyroidism,SHPT)、心血管事件和全因死亡的独立危险因素。本文综述了慢性肾脏病时高磷血症的调控机制及其不良预后的机制。

关键词: 慢性肾脏病, 高磷血症, 成纤维细胞生长因子-23, 继发性甲状旁腺功能亢进

Abstract: Chronic kidney disease (CKD) is highly prevalent in general population. With the decline of kidney function, the abnormality of phosphorus metabolism is gradually aggravated. In China, hyperphosphatemia in CKD is characterized by high prevalence and low control rate. Hyperphosphatemia is an independent risk factor of CKD progression, secondary hyperparathyroidism, cardiovascular events, and all-cause mortality in CKD patients. Literatures on mechanisms of hyperphosphatemia and its adverse outcomes were reviewed.

中图分类号: